Apatinib for Relapsed and Refractory Diffuse Large B Cell Lymphoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03376958|
Recruitment Status : Completed
First Posted : December 19, 2017
Last Update Posted : July 25, 2019
|Condition or disease||Intervention/treatment||Phase|
|Relapsed and Refractory Diffuse Large B Cell Lymphoma||Drug: Apatinib||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||32 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Apatinib for Relapsed and Refractory Difuse Large B Cell Lymphoma: an Open-label, Single Armed, Exploratory Study|
|Actual Study Start Date :||January 1, 2017|
|Actual Primary Completion Date :||February 1, 2019|
|Actual Study Completion Date :||April 30, 2019|
Apatinib 500mg once daily makes an initial dose and 28 days made one treatment cycle. All patients took the drug continuously until disease progression, intolerable toxicities, and patient-requested withdrawal. Appropriate supportive care were given.
Apatinib, a novel small molecule vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, have shown remarkable efficacy in many solid cancers. The result of our study presented that apatinib might have a rapid, safe and high efficacy on lymphoma patients.
- Overall Response Rate [ Time Frame: up to end of follow-up-phase ]The proportion of patients whose tumor volume has reduced to a predetermined value and can maintain the minimum time limit is the sum of complete and partial mitigation.
- Progression-free Survival [ Time Frame: up to end of follow-up-phase ]The time between the start of randomization and the progression of the tumor (any aspect) or (for any reason) death
- Overall Survival [ Time Frame: up to the date of death or end of follow-up-phase ]Time from randomization to death for any reason
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03376958
|Oncology Department of The First Affiliated Hospital of Zhengzhou University|
|Zhengzhou, Henan, China, 450052|